Anti-inflammatory effect of cardiac resynchronization therapy

PACE - Pacing and Clinical Electrophysiology

Volumn 29, Issue 7, 2006, Pages 753-758

  Lappegård, Knut T ^a   Bjørnstad, Hanne ^a  

^a NORDLAND HOSPITAL   (Norway)

Author keywords

Congestive heart failure; Immunology; Pacing

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CHEMOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD46; CARDIAC PACING, ARTIFICIAL; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; STATISTICS, NONPARAMETRIC;

EID: 33745951052     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2006.00430.x     Document Type: Article

References (41)

1. Hjalmarson A, Goldstein S, Fagerberg B, et al Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group [see comments]. JAMA 2000; 283:1295-1302.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
4. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62:60A-66A.
5. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362:759-766.
6. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
7. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97:1136-1143.
8. Aukrust P, Gullestad L, Lappegård KT, et al. Complement activation in patients with congestive heart failure: Effect of high-dose intravenous immunoglobulin treatment. Circulation 2001; 104:1494-1500.
9. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220-225.
10. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
11. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-1549.
12. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005; 28:304-310.
13. Fure H, Nielsen EW, Hack CE, Mollnes TE. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand J Immunol 1997; 46:553-557.
14. Wolbink GJ, Bollen J, Baars JW, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163:67-76.
15. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100:1869-1877.
16. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27:329-335.
17. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22:197-202.
18. Andreassen AK, Nordoy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998; 81:604-608.
19. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83:376-382.
20. Ceconi C, Curello S, Bachetti T, Corti A, Ferrari R. Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium? Prog Cardiovasc Dis 1998; 41(Suppl 1):25-30.
21. Dibbs Z, Kurrelmeyer K, Kalra D, et al. Cytokines in heart failure: Pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 1999; 111:423-428.
22. Kirsner AB, Hess EV, Fowler NO. Immunologic findings in idiopathic cardiomyopathy: A prospective serial study. Am Heart J 1973; 86:625-630.
23. Niebauer J. Inflammatory mediators in heart failure. Int J Cardiol 2000; 72:209-213.
24. Pritchett G, Cohen HJ, Murali KRK, Cobb F, Sullivan M, Currie MS. Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. Gerontology 1995; 41:45-56.
25. Mari D, Di Berardino F, Cugno M. Chronic heart failure and the immune system. Clin Rev Allergy Immunol 2002; 23:325-340.
26. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study [see comments]. Lancet 1999; 353:1838-1842.
27. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81:627-635.
28. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34:2061-2067.
29. Gullestad L, Ueland T, Brunsvig A, et al. Effect of metoprolol on cytokine levels in chronic heart failure - A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 2001; 141:418-421.
30. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000; 35:714-721.
31. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123-130.
32. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
34. Zhao SP, Zeng LH. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol 1997; 58:257-261.
35. Bozkurt B, Kribbs SB, Clubb FJ, Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382-1391.
36. Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure - Possible role of platelets and monocytes. Cardiovasc Res 2000; 45:428-436.
37. Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 2001; 3:415-421.
38. Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004; 19:237-241.
39. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol 2003; 24:36-43.
40. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 1999; 100:1102-1108.
41. Loppnow H, Werdan K, Werner C. The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; STNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist. Auton Autacoid Pharmacol 2002; 22:83-92.